Optomed Oyj Class A · OMXHEX:OPTOMED

Optomed Oyj Class A — Q4 2022 Earnings Presentation

16 slides from Optomed Oyj Class A's earnings presentation, Feb 17, 2023

  1. Slide 1: Optomed Q4 2022

    Optomed Q4 2022 17th February 2023 Seppo Kopsala, CEO Sakari Knuutti, CFO

  2. Slide 2: Q4/2022 Highlights

    Q4/2022 Highlights 1. 2. 3. Continued double-digit Improved EBITDA Financing round revenue growth, this and cashflow completed time driven by our Software Segment

  3. Slide 3: Q4/2022 Key Figures

    Q4/2022 Key Figures REVENUE GROWTH WAS DRIVEN BY OUR SOFTWARE SEGMENT THAT GREW 23.2% Q4/2022 Q4/2021 Change Revenue 4,013 3,552 13.0% Gross profit 1) 2,764 2,407 14.8% Gross margin 2) 68.9% 67.8% EBITDA -347 -1,528 77.3% EBITDA margin -8.7% -43.0% Net profit / loss -1,397 -1,936 27.8% Earnings per

  4. Slide 4: FY 2022 Key Figures

    FY 2022 Key Figures THE FULL YEAR REVENUE WAS FLAT IN SPITE OF EUR ~1.5 MILLION LESS REVENUE FROM CHINA FY 2022 FY 2021 Change Revenue 14,660 14,850 -1.3% Gross profit 1) 10,069 10,558 -4.6% Gross margin 2) 68.7% 71.1% EBITDA -1,952 -2,002 2.5% EBITDA margin -13.3% -13.5% Net profit / loss -5,472 -4

  5. Slide 5: Segment highlights

    Segment highlights OPT@MED

  6. Slide 6: Devices Segment Q4-2022

    Devices Segment Q4-2022 DEVICES’ REVENUE DECLINED SLIGHTLY IN Q4 BUT INCREASED +19% IN H2 DUE TO VERY STRONG Q3 Q4/2022 Q4/2021 Change A slight decline in revenue after 1. after extremely strong growth of 45.4 percent in Q3 Revenue 1,275 1,329 -4.0 % The gross margin was supported especially by a pr

  7. Slide 7: Software Segment Q4-2022

    Software Segment Q4-2022 OUR SOFTWARE SEGMENT HAD A VERY GOOD QUARTER Q4/2022 Q4/2021 Change Revenue increased by 23 % and 1. EBITDA margin improved Revenue 2,738 2,223 23.2 % The increase was driven by very Gross profit 1,900 1,643 15.6 % 2. strong performance of the healthcare solution business Gr

  8. Slide 8: Cash Flow

    Cash Flow EUR 4.1 MILLION COLLECTED FROM THE MARKET AND OPERATIVE CASH FLOW IMPROVED Q4 2022 Q4 2021 Loss for the financial year -1,397 -1,936 Cash flows before change -275 -906 in net working capital • Net cash from operating activities was 109 negative Change in net working capital 233 474 Cash fl

  9. Slide 9: Outlook 2023

    Outlook 2023 NEW OUTLOOK INDICATES GROWTH FOR FY 23 Supporting our Burdening our performance performance The outlook for 2023: + In mid-term, - Continuing new product weak market “Optomed expects its full year 2023 launches environment in revenue to grow compared to 2022.” China

  10. Slide 10: New US Business Model – Recurring Revenue

    New US Business Model – Recurring Revenue IN THE NEXT 5-10 YEARS, THERE WILL BE AT LEAST 50k – 100k FUNDUS CAMERAS CONNECTED TO AI IN THE US Complete Solution Business Model Customer Benefits From product sales to complete screening solutions with diagnosis Solution leased, not No initial investment

  11. Slide 11: Optomed's mission is to prevent blindness by improving access to eye screening globally

    Optomed’s mission is to prevent blindness by improving access to eye screening globally Bringing AI-integrated Expansion into new Opening new customer health screening to the geographical markets segments: primary care market

  12. Slide 12: Appendix

    Appendix

  13. Slide 13: Devices Segment: Key Financials FY 2022

    Devices Segment: Key Financials FY 2022 1-12/2022 1-12/2021 Change % Revenue 5,398 5,839 -7.6 % Gross profit 3,738 4,139 -9.7 % Gross margin 69.3 % 70.9 % EBITDA -670 -1,014 33.9 % EBITDA margin -12.4 % -17.4 %

  14. Slide 14: Software Segment: Key Financials FY 2022

    Software Segment: Key Financials FY 2022 1-12/2022 1-12/2021 Change % Revenue 9,263 9,011 2.8 % Gross profit 6,330 6,420 -1.4 % Gross margin 68.3 % 71.2 % EBITDA 2,079 1,855 12.1 % EBITDA margin 22.4 % 20.6 %

  15. Slide 15: Cash Flow: FY 2022

    Cash Flow: FY 2022 1-12/2022 1-12/2021 Loss for the financial year -5,472 -4,249 Cash flows before change in net working capital -2,479 -1,579 Change in net working capital 308 -1,233 Cash flows before finance items -2,171 -2,811 Cash flows from finance items -199 -129 Net cash from operating activi

  16. Slide 16: Balance Sheet

    Balance Sheet 31 December 2022 31 December 2021 • Equity ratio of 65.0 (58.8) ASSETS percent Goodwill 4,256 4,256 Development costs 6,562 6,338 • Total borrowings of EUR 5.3 Other intangible assets 2,077 2,380 Total intangible assets 12,895 12,975 (7.0) million Total tangible assets 2,315 1,652 Tota

Optomed — Q4 2022 Earnings Presentation on 6ix